Soshi Nagaoka
Lilly Plaza One Building, 5-1-28 Isogamidori, Chuo Ku
Kobe, 6510086, Japan
Kobe, 6510086, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer.
Journal: Drugs - real world outcomes
Published: March 15, 2023
Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real-world clinical practice: 36 month post-marketing observational study.
Journal: Journal of diabetes investigation
Published: July 03, 2022
Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in Japan.
Journal: Expert opinion on drug safety
Published: December 23, 2021
A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer.
Journal: Journal of gastrointestinal oncology
Published: December 09, 2021
A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: November 24, 2020
Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study.
Journal: Current medical research and opinion
Published: October 08, 2020
Incidence of Proteinuria among Japanese Colorectal Cancer Patients after Receiving Ramucirumab-Cohort Study Using Claim Database
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: June 17, 2020
Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study.
Journal: Current medical research and opinion
Published: April 10, 2020
Safety profiles of gemcitabine hydrochloride(GEMZAR®)in Japanese clinical studies
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: December 23, 2011
Showing 1-10 of 10
Last Updated: 09/26/2026